Jazz Pharmaceuticals plc logo JAZZ - Jazz Pharmaceuticals plc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 43
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $282.31 DETAILS
HIGH: $315.00
LOW: $229.00
MEDIAN: $287.00
CONSENSUS: $282.31
UPSIDE: 11.02%

Stock News

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating.

Aug 12, 2026 06:42 AM • seekingalpha.com
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment  DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor.

Aug 10, 2026 03:30 AM • prnewswire.com
Jazz Pharmaceuticals Q2 Earnings Call Highlights

Jazz Pharmaceuticals Q2 Earnings Call Highlights

Jazz Pharmaceuticals NASDAQ: JAZZ reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly sales. The company raised its full-year revenue outlook and said it is preparing for a potential August approval and launch of zanidatamab in first-line HER2-positive metastatic gastroesophageal adenocarcinoma, or GEA.

Aug 03, 2026 02:04 PM • marketbeat.com
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval – – Xywav® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex® revenues grew 16% YoY – DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. "Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.

Aug 03, 2026 12:05 PM • prnewswire.com
Aristotle Global Equity Advisory Q2 2026 Portfolio Review

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.

Jul 29, 2026 09:20 PM • seekingalpha.com

Price Targets